Evaluation of antidiarrheal, antiulcer, anti-collagenase and cholesterol lowering activity of Heyndrickxia coagulans MTCC 25308 (Bacospore®)

Pratyusha Dhabadi; Shreya; Akhina Tom; Shreya Shivashankara; Zayeem Firoz Hussain; Firoz Hirehal Hussain Mirza; Sadashiva Channangihalli Thimmegowda

doi:10.18203/2319-2003.ijbcp20262859

Authors

Pratyusha Dhabadi Department of Research and Development, Star Hi Herbs Pvt Ltd, Jigani, Bangalore, Karnataka, India
Shreya Department of Research and Development, Star Hi Herbs Pvt Ltd, Jigani, Bangalore, Karnataka, India https://orcid.org/0009-0007-9526-9561
Akhina Tom Department of Research and Development, Star Hi Herbs Pvt Ltd, Jigani, Bangalore, Karnataka, India https://orcid.org/0009-0009-4861-2800
Shreya Shivashankara Department of Research and Development, Star Hi Herbs Pvt Ltd, Jigani, Bangalore, Karnataka, India https://orcid.org/0009-0002-9022-4421
Zayeem Firoz Hussain Department of Biotechnology, Oxford College of Engineering, Bangalore, Karnataka, India
Firoz Hirehal Hussain Mirza Department of Research and Development, Star Hi Herbs Pvt Ltd, Jigani, Bangalore, Karnataka, India https://orcid.org/0009-0002-5576-9047
Sadashiva Channangihalli Thimmegowda Department of Research and Development, Star Hi Herbs Pvt Ltd, Jigani, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20262859

Keywords:

Bile salt hydrolase, Collagenase inhibition, Gastroprotective activity, Heyndrickxia coagulans, Lipid metabolism

Abstract

Background: Probiotics are increasingly recognized for their role in promoting gastrointestinal health and metabolic regulation. The present study investigated the multifunctional biological activities of Heyndrickxia coagulans (formerly Bacillus coagulans) MTCC 25308 (Bacospore^®), focusing on its antiulcer, antidiarrheal, cholesterol-lowering, and anti-collagenase properties.

Methods: Antiulcer activity was evaluated in rats using an ethanol-induced gastric ulcer model. Bacospore^® was administered orally at doses of 100 and 200 mg/kg body weight, and its effects were compared with ranitidine (20 mg/kg body weight). Antidiarrheal activity was assessed in a castor oil-induced diarrhea model using the same doses and compared with loperamide. Anti-collagenase activity was determined in vitro using enzyme inhibition assays, while cholesterol-lowering potential was assessed through bile salt hydrolase (BSH)-mediated cholesterol reduction assays.

Results: Bacospore^® exhibited significant gastroprotective activity against ethanol-induced gastric ulcers, with the highest ulcer inhibition observed at 200 mg/kg body weight, surpassing the protective effect of ranitidine. In the castor oil-induced diarrhea model, Bacospore^® demonstrated notable antidiarrheal activity comparable to the standard treatment. In vitro studies showed strong collagenase inhibition, reaching 85% at 200 µg/ml, indicating potential extracellular matrix-protective effects. Additionally, Bacospore^® achieved 97.72% cholesterol reduction at 1000 µg/ml through BSH-mediated bile salt deconjugation, suggesting substantial hypocholesterolemic potential.

Conclusions: Heyndrickxia coagulans MTCC 25308 (Bacospore^®) demonstrated significant antiulcer, antidiarrheal, anti-collagenase, and cholesterol-lowering activities. These findings suggest that Bacospore^® exerts pleiotropic health benefits through modulation of gastrointestinal function, enzymatic activity, and lipid metabolism, supporting its potential as a multifunctional next-generation probiotic for managing gastrointestinal disorders and metabolic dysregulation.

References

Food and Agriculture Organization of the United Nations, World Health Organization. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. 1st ed. Available at: https://www.scirp.org/reference/referencespapers?referenceid=1456307. Accessed on 1 May 2026.

Fuller R. Probiotics in human medicine. Gut. 1991;32(4):439-42.

Krishnareddy S, Green PHR. Celiac disease, the microbiome, and probiotics. In: Floch MH, Ringel Y, Walker WA, eds. The Microbiota in Gastrointestinal Pathophysiology. Oxford: Academic Press; 2017:365-371.

Anders ME, Akkermans LM, Haller D, Hammerman C, Heimbach JT, Hörmannsperger G, et al. Safety assessment of probiotics for human use. Gut Micro. 2010;1(3):164-85.

Hyronimus B, Le Marrec C, Sassi AH, Deschamps A. Acid and bile tolerance of spore-forming lactic acid bacteria. Int J Food Microbiol. 2000;61(2-3):193-7.

Endres JR, Clewell A, Jade KA, Farber T, Hauswirth J, Schauss AG. Safety assessment of a proprietary preparation of a novel probiotic, Bacillus coagulans, as a food ingredient. Food Chem Toxicol. 2009;47(6):1231-8.

Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, et al. Corrigendum to “cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases”. J Diabetes Res. 2022;2022:3952529.

Lye HS, Rahmat-Ali GR, Liong MT. Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. Int Dairy J 2010;20(3):169-75.

Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491-4.

Tsukahara T, Fujimori A, Misawa Y, Oda H, Yamauchi K, Abe F, et al. The preventive effect of lactoferrin-containing yogurt on gastroenteritis in nursery school children: intervention study for 15 weeks. Int J Environ Res Public Health. 2020;17(7):2534.

Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29(9):938-46.

Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 2004;70(1):518-26.

Payne J, Bellmer D, Jadeja R, Muriana P. The potential of Bacillus species as probiotics in the food industry: a review. Foods. 2024;13(15):2444.

Guarino A, Guandalini S, Lo Vecchio A. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2015;49(Suppl 1):S37-45.

Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15:21.

Moore S, Stein WH. Photometric ninhydrin method for use in the chromatography of amino acids. J Biol Chem. 1948;176(1):367-88.

Mandl I, MacLennan JD, Howes EL, DeBellis RH, Sohler A. Isolation and characterization of proteinase and collagenase from Cl. histolyticum. J Clin Invest. 1953;32(12):1323-9.

Oelschlaeger TA. Mechanisms of probiotic actions- a review. Int J Med Microbiol. 2010;300(1):57-62.

Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, et al. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62(5):787-96.

Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119-24.

Greaves MW. Physiology of skin. J Invest Dermatol. 1976;67(1):66-9.

Varani J, Spearman D, Perone P, Fligiel SE, Datta SC, Wang ZQ, et al. Inhibition of type I procollagen synthesis by damaged collagen in photoaged skin and by collagenase-degraded collagen in vitro. Am J Pathol. 2001;158(3):931-42.

Majeed M, Majeed S, Nagabhushanam K, Arumugam S, Beede K, Ali F. Evaluation of the in vitro cholesterol-lowering activity of the probiotic strain Bacillus coagulans MTCC 5856. Int J Food Sci Tech. 2019;54:212-20.

Carey MC, Duane WC. Enterohepatic circulation. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, eds. The liver: biology and pathobiology. New York, NY: Raven Press; 1994:719-738.

Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006;72(3):1729-38.

He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci. 2017;7:54.

Elshaghabee FMF, Rokana N, Gulhane RD, Sharma C, Panwar H. Bacillus as potential probiotics: status, concerns, and future perspectives. Front Microbiol. 2017;8:1490.

Pereira DI, McCartney AL, Gibson GR. An in vitro study of the probiotic potential of a bile-salt-hydrolyzing Lactobacillus fermentum strain, and determination of its cholesterol-lowering properties. Appl Environ Microbiol. 2003;69(8):4743-52.

Li G. Intestinal probiotics: interactions with bile salts and reduction of cholesterol. Procedia Environ Sci. 2012;12(B):1180-6.

Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. Exp Ther Med. 2016;12(1):3-17.